Buradasınız

Anasayfa » Content

GLIOBLASTOMA' DA PROGNOZU ETKİLEYEN FAKTÖRLER

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 1999
Author NameUniversity of AuthorFaculty of Author
Bookmark/Search this post with
Abstract (Original Language): 
Glioblastom (GB) genellikle beyinde yerleşmesine karşın, beyincik, beyin sapı ve omurilikte de yerleşebilir. GB'de birçok tedavi modellerinin kullanılmasına rağmen yaşam süreleri henüz arzulanan düzeylerde değildir. Prognoz; yaş, cins, öykü süresi, başlangç ve tedavi sonrası klinik tablo (Kamofsky Performans Skalası-KPS), tümör boyutu ve yerleşimi, cerrahi rezeksiyon oranı, brakiterapi, radyoterapi (RT) ve/veya kemoterapı uygulanması ve bu tedavilere yanıtı, histopatolo-jik olarakta nekroz, hemoraji ve tromboz varlığı gibi bulgulara bağlı olarak değişmektedir d.2,6). Beklenen yaşam süreleri agresif cerrahi ve ilave tedavilere karşın genellikle 1 yıldır, an¬cak 10 yıla kadar uzayan nadir yaşam süreleri bildirilmiştir (2,6,14,17),
FULL TEXT (PDF): 
PDF icon arastirmax-glioblastoma-da-prognozu-etkileyen-faktorler.pdf
  • 2
220-223
  • Turkish

REFERENCES

References: 

1. Barker FG, Davis RL, Chang SM, Prados MD: Necrosis as a prognostic factor in Glioblastoma muitiforme. Can-cer 77:1161 (1996).
2. Barker FG, Prados MD, Chang SM, Gutin PH, Lamborn KR, Larson DA, Malec MK, McDermott MW, Sneed PK, Wara MW, Wilson CB: Radiation response and sur-vival time in patients with glioblastoma muitiforme. J Neurosurg 84:442 (1996).
3. Barker FG, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, Wilson CB: Survival and functio-nal status after reseclİon of recurrent giioblastoma muitiforme. Neurosurgery 42:709 (1998).
4. Bindai AK, Hammoud M, Shi WM, Wu SZ, Sawaya R, Rao JS: Prognostic significance of proteolytic enzymes in human brain tumors J Neurooncol 22:101 (1994).
5. Burger PC, Vogcl FS, Grecn SB, Strike TA: Glioblastoma muitiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56:1106 (1985).
6. Durmaz R, Erken S, Arslaııtaş A, Atasoy MA, Bal C, Tel E: Management of glioblastoma muitiforme: with special reference to recurrence. Clin Neurol Neurosurg 99:117 (1997).
7. Ellison DW, Steart PV, Batcman AC, Pickering RM, Palmer JD, Weller RO: Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psych 59:413 (1995).
8. Jeremic B, Grujicic D, Antunovic V, Djuric L, Stojano-vic M, Shibamoto Y: İnfluence of exlent of surgery and tumor location on treatment outcomc of patients wifh glioblastoma muitiforme treated with combined modality approachj Neurooncol 21:177 (1994).
9. Kim TS, Haliiday AL, Hedley-WhitcET, Convery K: Correlates of survival and Daıımas-Dupport grading system for astrocytomas. J Neurosurg 74:27 (1991).
10. Kleihues P, Burger PC, Scheithauer BW: Histologic typing of tumours of the central nervous system. Sprin-ger-Verlag, Berlin. (1993).
11. Leon SP, Folkerth RD, Black PM: Microvessel density is
a prognostic indicator for patients vvith astroglial brain tumors. Cancer 77: 362 (1996).
12. Mikkelsen T, Yan PS, Ho KL, Sameni M, Sloane BF, Rosenbium ML: Immunolocalİzation of catepsin B in human giioma: implications for tumor invasion and angio-gencsis. J Neurosurg 83:285 (1995).
13. Morrison RS, Yamaguchi F, Bruncr JM, Tang M, McKe-chan W, Berger MS: Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human giioblastoma muitiforme. Cancer Res 54: 2794 (1994).
14. Poilak L, Gur R, Walach N, Reif R, Tamir L, Schiffer J: Clinical determinants of long-term survival in patients wilh glioblastoma muitiforme. Tumori 83: 613 (1997).
15. Rainov NG, Dobberstein KU, Bahn H, Holzhausen H-J, Lautenschîager C, Heidecke V, Burkert W: Prognostic factors in malignant giioma: influence of the overexpres-sion of oncogene and tumor suppressor gene products on survival. J Neurooncol 35: 13(1997).
16. Revesz T, Scaravili F, Coulinho L, Cockburn H, Sacares P, Thomas DG: Rcliabilİty of histological diagnosis inc-luding grading in güomas biopsied by image-guidcd ste-reotactic technique. Brain 116:781 (1993).
17. Ritter AM, Sawaya R, Hess KR, Levin VA, Bruner JM: Prognostic significance of Bromodeoxyuridine-labeling in primary and recurrent glioblastoma muitiforme. Neurosurgery 35: 192 (1994).
18. Schober R, Bilzer T, Waha A, Reifenberger G, Wechsler W, von Deimling A, Wiestler OD, Westphal M, Kems-head JT, Vega F: The epidermaî growth factor receptor in gliobiastoma: genomic ampîification, protein expressi-on, and patient survival data in a therapeutic triaİ. Clin Neuropathol 14:169(1995).
19. Stemmer-Rachmaninov AO, Louis DN: Histopathologic and İmmunohistochemical prognostic factors in malignant tumors. CUIT Opin in Oncol 9:230 (1997).
20. 66th Annual Meeting of AANS. Scientific Program. Phi-ladelphia, Pennsylvania: The American Association of Neurological Surgcons, April 25-30, (1998).
21. 66fh Annual Meetİng of AANS. Poster Program. Phüa-delphİa, Pennsylvania: The American Association of Neurological Surgeons, April 25-30, 227 (1998).

Thank you for copying data from http://www.arastirmax.com